Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

Novo Nordisk’s ($NVO) shares in Copenhagen closed roughly 5% higher on Friday. This came after Nordea ($NRDBY) went bullish on the Danish drugmaker...

Novo Nordisk Stock Climbs as Analyst Flags Potential for More Wegovy Pill Sales

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novo Nordisk today and set a price target of DKK290.00. According to TipRanks,...

Deutsche Bank  Remains a Hold on Novo Nordisk (0QIU)

Danish drugmaker Novo Nordisk’s ($NVO) shares in Copenhagen rose about 5% on Friday. This coincides with Novo Nordisk Foundation, the company’s maj...

Novo Nordisk Stock Jumps as Owner Launches Obesity Research Network

WSW, NY, June 17th, 2026, FinanceWire Rhythm&rsquo;s latest rare-obesity win strengthens the MC4R thesis – making Palatin&rsquo;s more selective, n...

Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The study, officially titled “Descriptive Study for Turoctocog Alfa Treatm...

Novo Nordisk’s Iraq Haemophilia Study Adds Real‑World Support for Turoctocog Alfa

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Novo Nordisk today and set a price target of DKK325.00. Holford covers the Healthca...

Berenberg Bank Remains a Buy on Novo Nordisk (0QIU)

Novo Nordisk ($NVO) is stepping up its competition with rival Eli Lilly ($LLY) in China’s oral weight loss drug market. According to a Reuters repo...

Novo Nordisk Seeks China Approval for Wegovy Pill, Intensifying Rivalry with Lilly

Novo Nordisk ( ($NVO) ) has issued an announcement. On 15 June 2026, Novo Nordisk provided an update on its ongoing share repurchase programme laun...

Novo Nordisk Expands 2026 Share Buyback, Holding 0.8% of Capital in Treasury Shares

Most Americans have health insurance through their employer. 


Eli Lilly Stock (LLY) Dips on Reports Employers Plan to Drop Weight-Loss Drug Coverage

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Novo Nordisk, with a price target of DKK290.00. Papad...

The pharma giant is looking to extend its lead in the obesity drug market. 


Eli Lilly Stock (LLY) Jumps 4%. The Outlook for Its Weight-Loss Drugs Just Keeps Getting Better

An update from Novo Nordisk ( ($NVO) ) is now available. Novo Nordisk, the Danish healthcare group focused on chronic diseases such as diabetes, co...

Novo Nordisk Advances DKK 15 Billion Share Buyback as Treasury Stake Reaches 0.8%

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cullinan Management (CGEM), Pfizer (PFE) and Novo ...

Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO)

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novo Nordisk today and set a price target of DKK250.00. According to TipRanks, Vosse...

J.P. Morgan Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Eli Lilly and Company ($LLY) gave investors another reason to watch its obesity pipeline after new late-stage data showed that its experimental dru...

Eli Lilly’s Retatrutide Gives LLY Stock a Fresh Obesity Drug Catalyst

The company recently launched a new pill version of its weight-loss drug. 


Jim Cramer Sees Eli Lilly (LLY) Delivering ‘Knockout Punch’ to Competitors

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk (NVO) has launched a Phase 1 trial titled “Investigation of t...

Novo Nordisk Expands Obesity and Diabetes Pipeline With New Phase 1 Trial of NNC0497-0040

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk (NVO) has launched a first‑in‑human trial titled “A First in ...

Novo Nordisk Expands Obesity Pipeline With New First‑in‑Human Trial for NNC0113-5840

ASML stock ($ASML) ignited during Wednesday morning trading as the business crushed European records to become the most valuable company in the reg...

ASML Stock Crushes European Records as JPMorgan Analyst Warns Investors Are “Behind the Curve”

NY, WSW, June 1st, 2026, FinanceWire Peptides are having a moment – and for good reason. They represent one of the most productive frontiers in mod...

Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk (NVO) is running a Phase 3 trial called “A Clinical Study to ...

Novo Nordisk’s CagriSema Trial Puts Next-Generation Obesity Strategy in Focus

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novo Nordisk today and set a price target of DKK290.00. Papadakis covers the H...

Deutsche Bank  Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Indications are that the new weight-loss pill is selling well. 


Eli Lilly Stock (LLY) Gets a Price Target Boost as Weight-Loss Drug Sales Accelerate

In a report released on May 22, David Evans from Kepler Capital maintained a Hold rating on Novo Nordisk, with a price target of DKK290.00. The com...

Kepler Capital  Keeps Their Hold Rating on Novo Nordisk (0QIU)

Novo Nordisk ( ($NVO) ) just unveiled an announcement. Novo Nordisk said on 22 May 2026 that the European Medicines Agency’s Committee for Medicina...

Novo Nordisk Wins EMA Panel Backing for First Oral Wegovy Obesity Pill in EU

The latest update is out from Novo Nordisk ( ($NVO) ). On May 22, 2026, Novo Nordisk announced that the European Medicines Agency’s Committee for M...

Novo Nordisk Wins CHMP Backing for High-Dose Wegovy Single-Dose Pen in EU

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk is running a phase 3 study called AMAZE 3 to test a new weekl...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVO	$43.19	-0.76%	9.00M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVO	$43.19	-0.8%	9.00M
3
4
5
6

NVO

NVO

Recent News for NVO

Get Novo Nordisk A/S Data in Excel

Get Novo Nordisk A/S Data in Excel